BCANTT 2020: High-Risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer: Vicineum

(UroToday.com) Rian Dickstein, MD, from Chesapeake Urology, presented on vicineum in bacillus calmette-guerin (BCG) unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). Vicineum is a recombinant fusion protein antibody linked to a variant of pseudomonas exotoxin A (ETA) which is administered intravesically for 2 hours twice weekly with induction x 6wks and maintenance weekly for 6 weeks. The phase III trial data in high-risk BCG unresponsive NMIBC was discussed: Cohort 1= Carcinoma in situ (CIS) refractor, Cohort 2= CIS papillary tumors, Cohort 3= no CIS. At 3 months there was 40% CR with CIS with 39% CR at 15 months. At 3 months, 71% recurrence-free survival (RFS) was observed, and 50% probability RFS at 12 months. Toxicity minimal with 4% had Grade 3/4 toxicity. A planned confirmatory trial is underway. Another concentration trial is also underway.

Presented by: Rian Dickstein, MD, Chesapeake Urology, University of Maryland Medical System, Hanover, Maryland 

Written by: Stephen B. Williams, MD, Medical Director for High-Value Care; Chief of Urology, Professor, Director of Urologic Oncology, Director Urologic Research, The University of Texas Medical Branch at Galveston, TX at the 2020 Virtual Bladder Cancer Advocacy Network Think Tank 2020